TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02398032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP nasal
Description: During the night

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP nasal
Description: During the night
Study: NCT02386839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Description: Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Description: Participants who received rhIGF-1/rhIGFBP-3 in study ROPP-2008-01 (NCT01096784) will be enrolled to this study. No investigational product will be administered in this study.
Study: NCT02405897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cup forceps
Description: In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alligator forceps
Description: In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
Study: NCT02280512

Intervention type: DEVICE
Intervention: elderly with fractures
Description: hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
Study: NCT03893110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical stabilization of the spine due to primary and secondary spinal tumors
Description: Posterior instrumentation with pedicle screw system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical stabilization of the spine due to primary and secondary spinal tumors
Description: Posterior instrumentation with pedicle screw system
Study: NCT01939301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Nitric Oxide
Description: Nitric Oxide + oxygen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: Nitrogen + Oxygen
Study: NCT02201901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT01654068

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conformal High Dose Intensity Modulated Radiation Therapy
Description: Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
Study: NCT00495092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: Biperiden 2-4 mg/d p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + Placebo
Study: NCT01611961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT-LM
Description: Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
Study: NCT04306146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAD-9303
Description: Capsules filled with CAD-9303 from 3 mg up to 1000 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Capsules
Study: NCT02975791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Marking the cricothyroid membrane after ultrasound
Description: Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marking of the cricothyroid membrane after Palpation
Description: Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
Study: NCT01765790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Description: * Dosing every 2 weeks~* Intravenous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Description: * Dosing weekly~* Intravenous injection
Study: NCT03638921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
Study: NCT00583947

Intervention type: DRUG
Group type: OTHER
Intervention: arformoterol
Description: Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).

Intervention type: DRUG
Group type: OTHER
Intervention: arformoterol
Description: Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).

Intervention type: DRUG
Group type: OTHER
Intervention: levalbuterol
Description: Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).

Intervention type: DRUG
Group type: OTHER
Intervention: levalbuterol
Description: Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
Study: NCT04568863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin intravenous
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours.
Study: NCT04246398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FMT - placebo
Description: Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake.~Each capsule will be taken with a sip of water, Capsules must not be crushed, chewed, or dissolved Participants will be evaluated for 15 minutes immediately following capsule administration.
Study: NCT01972997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study: NCT01398696

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Information Leaflets
Description: Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: usual consultation
Description: No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
Study: NCT05129410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 1. Prednisone 0.5-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after oral administration for 3 months, and then reduced to 7.5mg/d for maintenance therapy until 12 months;~2. MMF1.5g-2.0g/d
Study: NCT00809679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-62 Dose 1
Description: Capsule dosage form 100 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-62 Dose 2
Description: Capsule dosage form 200 mg bid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule dosage form placebo bid
Study: NCT01550055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB009 plus Irinotecan
Description: Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan-only and sequential-CMAB009
Description: First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
Study: NCT01237847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Family-based problem solving phone sessions
Description: 2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Family-based problem solving phone intervention sessions
Description: 4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list comparison group
Description: Wait list comparison group to receive intervention at later point.
Study: NCT02336256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedures of hernia repair.
Description: We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedures of hernia repair.
Description: We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
Study: NCT00717548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: Trauma-Focused short term intervention (8-12 sessions)
Study: NCT03700905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection of primary tumor
Description: Surgical resection of primary tumor including neck dissection according to standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection of primary tumor
Description: Surgical resection of primary tumor including neck dissection according to standard of care

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radio(-chemo)therapy
Description: Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant radio(-chemo)therapy
Description: Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Nivolumab
Description: Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Nivolumab
Description: Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Nivolumab and Ipilimumab
Description: Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
Study: NCT00406614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy-Focused High Blood Pressure Intervention
Description: Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Literacy-Focused High Blood Pressure Intervention
Description: Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
Study: NCT01268124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTC-867
Study: NCT01728571

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Study: NCT04142411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Ultrasound guided perineural injection therapy (PIT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Ultrasound guided perineural injection therapy (PIT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: Ultrasound guided perineural injection therapy (PIT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Ultrasound guided perineural injection therapy (PIT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Philips Neuromuscular Ultrasound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Philips Neuromuscular Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Philips Neuromuscular Ultrasound
Study: NCT02977299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Description: Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
Study: NCT00803777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Blood Glucose Monitoring System
Description: Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
Study: NCT00130845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate in Microspheres

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00624910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Collagen Sponge (CollaRx®)
Description: The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
Study: NCT02573272

Intervention type: DRUG
Intervention: eslicarbacepine
Study: NCT03376035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature measurement of breast
Description: Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temperature measurement of breast
Description: Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
Study: NCT01898780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy with horizontal mattress suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pancreaticojejunostomy with interrupted suture
Study: NCT00960609

Intervention type: PROCEDURE
Intervention: Ultrasound guided liver resection
Study: NCT01289132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan
Description: Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
Study: NCT03436303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/MP 100mg
Description: CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/MP 100mg
Description: CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEE 0.625mg/dydrogesterone
Description: CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
Study: NCT02246881

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Optivate® (Human Coagulation Factor VIII)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Optivate® (Human Coagulation Factor VIII)
Study: NCT02432170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis of Foot and Ankle
Description: Imaging Technique
Study: NCT01278147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fatigue education program
Description: the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
Study: NCT04729842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Brachial plexus block
Description: Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary Brachial plexus block
Description: Brachial plexus block via axillary route was administered using 30 ml of 0.5% Bupivacaine in group B and 30 ml of 0.5% Ropivacaine in Group R
Study: NCT01789840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embosphere Microspheres

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Study: NCT00908349

Intervention type: DRUG
Group type: OTHER
Intervention: Oxcarbazepine XR
Description: Open Label Study
Study: NCT05328310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Treatment of nebivolol instead of telmisartan; the drug administration is mutually exclusive for the two arms.
Study: NCT02503826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: moderate dose
Study: NCT01728571

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo